Predictive factors for early super response to bimekizumab in 341 patients with psoriasis-a 24-week short-term multicenter real-life experience.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Çetinarslan Tubanur, Mergen Muhammed Ali, Türel Ermertcan Aylin, Bülbül Başkan Emel, Yazıcı Serkan, An İsa, Gürel Gülhan, Adışen Esra, Demirbaş Abdullah, Dursun Recep, Aslancan Bahadır, Topkarcı Zeynep, Esen Mustafa, Türkoğlu Zafer, Canat Dilek, Kandiş Selim, Kılıç Arzu, Ertam Sağduyu İlgen, Yazıcı Elif Irmak, Gökyayla Ece, Demirel Öğüt Neslihan, Karstarlı Bakay Özge Sevil, Temiz Selami Aykut, Erdemir Vefa Aslı, Hapa Fatma Aslı, Aydin Ömer, Hızlı Pelin, Solak Berna, Bütüner Melike, Aytekin Sema, Albayrak Hülya, Daye Munise, Türsen Ümit, Sarıbaş Yıldırım Ayşe Nur, Cengiz Özyurt Beyhan
Аннотация
MATERIALS AND METHODS: We performed a multicenter retrospective study in 20 Dermatology outpatient clinics in Turkey. Adult patients with moderate-to-severe psoriasis who were under bimekizumab for at least 12 weeks were enrolled.
RESULTS: A total of 341 adult patients were included. 136 had nail psoriasis (39.9%), 148 had psoriatic arthritis (PsA) (43.4%), 223 (65.4%) had at least one difficult-to-treat area involvement, 155 (45.5%) were bio-naïve, 110 (32.5%) had ≥ 2 biologics history. At week 4, PASI75 was achieved in 144 patients (49.8%), PASI90 was achieved in 88 patients (30.4%), PASI100 was achieved in 51 patients (17.6%). Family history (p = 0.041), palmoplantar involvement (p = 0.008), PsA (p = 0.097), and bio-experienced status (p = 0.060) were associated with lower odds of being an ESR, whereas each 1-point increase in baseline PASI was associated with significantly lower odds of ESR (p < 0.001). Gender, age, disease duration, history of conventional systemic treatment, and presence of any comorbidity were not significantly associated with the likelihood of being an ESR (all p > 0.05).
CONCLUSION: Bimekizumab is the effective treatment in both bio-naïve and bio-experienced patients; however, it may have a more rapid onset of action in bionaive patients. Further studies are needed on the long-term efficacy and safety data of bimekizumab.